Cytosorbents Corporation (NASDAQ: CTSO)
$1.13
+0.0550 ( +5.14% ) 136.2K
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Market Data
Open
$1.13
Previous close
$1.07
Volume
136.2K
Market cap
$60.82M
Day range
$1.05 - $1.14
52 week range
$0.70 - $3.88
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Sep 12, 2023 |
8-k | 8K-related | 14 | Sep 01, 2023 |
3 | Insider transactions | 2 | Aug 15, 2023 |
8-k | 8K-related | 12 | Aug 11, 2023 |
4 | Insider transactions | 1 | Aug 08, 2023 |
8-k | 8K-related | 14 | Aug 02, 2023 |
10-q | Quarterly Reports | 68 | Aug 01, 2023 |
8-k | 8K-related | 15 | Jul 19, 2023 |
4 | Insider transactions | 1 | Jul 11, 2023 |
4 | Insider transactions | 1 | Jul 11, 2023 |